Publication of a rectified transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
September 15, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian...
Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
September 12, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian...
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
September 07, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
September 05, 2023 16:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance,...
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
September 04, 2023 16:00 ET
|
Celyad Oncology SA
Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023Celyad Oncology has received approximately EUR 9.8m in private placement commitments from historical shareholdersEncouraging...
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
August 24, 2023 16:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Aug. 24, 2023 (GLOBE NEWSWIRE) -- regulated information / inside information - Celyad Oncology SA (“Celyad” or the “Company”) today announced that it has obtained...
Celyad Oncology announces receipt of Nasdaq delisting notice
May 15, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for...
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
May 05, 2023 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric...
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
May 05, 2023 01:00 ET
|
Celyad Oncology SA
Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of...
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
April 24, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric...